Work

749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.810

Authors: L.P. Martin, D. Uyar, A. Madariaga, A.I. Spira, A. Oaknin, R. Schilder, E.M. Guerra Alia, E.P. Hamilton, R.W. Naumann, D. Lorusso, L. Lu, C.J. Berman, A.E. Borgman, J.W. Moroney

Institutions: Abramson Cancer Center, University of Pennsylvania, Froedtert Hospital, Medical College of Wisconsin, Hospital Universitario 12 De Octubre, Virginia Cancer Specialists, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Thomas Jefferson University, Hospital Universitario Ramón y Cajal, Sarah Cannon, Levine Cancer Institute, Agostino Gemelli University Polyclinic, Sutro Biopharma (United States), University of Chicago

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Gilead Sciences, Ludwig Institute for Cancer Research, Clovis Oncology, BeiGene, Syndax Pharmaceuticals, Genentech

OpenAlex ID: W4402559912

FWCI: 1.175

Cites:

Cited by: 3

Related to: 10